Haemonetics (HAE)
(Delayed Data from NYSE)
$75.49 USD
-0.89 (-1.17%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $75.50 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$75.49 USD
-0.89 (-1.17%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $75.50 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth F Momentum F VGM
Zacks News
4 Medical Product Stocks to Buy From a Prospective Industry
by Indrajit Bandyopadhyay
Ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, BAX, HAE and PAHC are well-poised to gain from the favorable factors.
Medtronic (MDT) Up 0.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
HAE or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HAE vs. BSX: Which Stock Is the Better Value Option?
After Plunging -15.88% in 4 Weeks, Here's Why the Trend Might Reverse for Haemonetics (HAE)
by Zacks Equity Research
Haemonetics (HAE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
HAE vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
HAE vs. BSX: Which Stock Is the Better Value Option?
Implied Volatility Surging for Haemonetics (HAE) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Haemonetics (HAE) stock based on the movements in the options market lately.
Haemonetics (HAE) Set to Launch VASCADE MVP XL in US
by Zacks Equity Research
Haemonetics (HAE) expands its VASCADE portfolio with the full market release of the VASCADE MVP XL vascular closure device in the U.S. market.
Haemonetics (HAE) Q1 Earnings Miss Estimates, Gross Margin Rises
by Zacks Equity Research
Haemonetics' (HAE) earnings lag estimates in the first quarter of fiscal 2025. However, the company remains confident about its strategy for sustained profitable growth.
Is Haemonetics (HAE) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Down -14.6% in 4 Weeks, Here's Why Haemonetics (HAE) Looks Ripe for a Turnaround
by Zacks Equity Research
Haemonetics (HAE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
HAE or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HAE vs. BSX: Which Stock Is the Better Value Option?
Haemonetics (HAE) Misses Q1 Earnings Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of -0.97% and 0.09%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 30.13% Upside in Haemonetics (HAE): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 30.1% in Haemonetics (HAE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Verano Holdings Corp. (VRNOF) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Verano Holdings Corp. (VRNOF) delivered earnings and revenue surprises of 0% and 0.82%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Align Technology (ALGN) Encounters Low ASP, FX Headwinds
by Zacks Equity Research
Align Technology's (ALGN) Clear Aligner ASP is facing a significant impact of unfavorable foreign exchange across multiple currencies.
Is Phibro (PAHC) Stock Worth Retaining in Your Portfolio Now?
by Zacks Equity Research
Phibro's (PAHC) Animal Health business, supported by the flourishing Vaccine product line, drives optimism for future growth. However, macroeconomic impacts are a concern.
Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cerus (CERS) delivered earnings and revenue surprises of 25% and 6.07%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exact Sciences (EXAS) Q2 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Exact Sciences' (EXAS) second-quarter 2024 top-line results reflect robust revenues from the Screening and Precision Oncology segments.
Baxter's (BAX) Helion Surgical System Debuts in Thailand
by Zacks Equity Research
Baxter (BAX) launches the Helion Integrated Surgical System in Thailand, aiming to streamline operating room efficiency and enhance surgical team connectivity with cutting-edge technology.
Hospital Business Recovery to Aid Haemonetics' (HAE) Q1 Earnings
by Zacks Equity Research
Haemonetics' (HAE) first-quarter fiscal 2025 results are likely to reflect the benefits of hemostasis management growth.
Hologic (HOLX) Buys Endomag to Boost Breast Cancer Solutions
by Zacks Equity Research
Hologic (HOLX) acquires Endomag for $310M, enhancing its breast cancer surgery portfolio with innovative technologies like Magseed and Magtrace, aiming to improve patient care and outcomes globally.
ICON (ICLR) Q2 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
ICON's (ICLR) second-quarter 2024 results reflect efficient service delivery and strong cost control.
Terumo (TRUMY) Unit Reveals WEB 17 Device Effective in Aneurysms
by Zacks Equity Research
Terumo's (TRUMY) subsidiary MicroVention's WEB 17 device, used in treating intracranial aneurysms, demonstrates high safety and effectiveness in the CLEVER study.